Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment

Heart Rhythm. 2020 Jul;17(7):e231-e232. doi: 10.1016/j.hrthm.2020.04.016. Epub 2020 Apr 14.

Authors

Dan M Roden¹, Robert A Harrington², Athena Poppas³, Andrea M Russo⁴

Affiliations

¹ Interim Division Chief, Division of Cardiovascular Medicine, Vanderbilt University School of Medicine. Electronic address: [email protected].
² President of the American Heart Association.
³ President of the American College of Cardiology.
⁴ President of the Heart Rhythm Society.

No abstract available

Publication types

Practice Guideline

MeSH terms

Anti-Infective Agents / administration & dosage
Anti-Infective Agents / adverse effects
Azithromycin* / administration & dosage
Azithromycin* / adverse effects
Betacoronavirus / drug effects
COVID-19
COVID-19 Drug Treatment
Contraindications, Drug
Coronavirus Infections / complications
Coronavirus Infections / drug therapy*
Drug Interactions
Drug Monitoring / methods
Drug Therapy, Combination / adverse effects
Drug Therapy, Combination / methods
Electrocardiography / methods
Humans
Hydroxychloroquine* / administration & dosage
Hydroxychloroquine* / adverse effects
Long QT Syndrome* / chemically induced
Long QT Syndrome* / diagnosis
Long QT Syndrome* / prevention & control
Pandemics
Pneumonia, Viral / drug therapy*
SARS-CoV-2
Torsades de Pointes* / chemically induced
Torsades de Pointes* / diagnosis
Torsades de Pointes* / prevention & control

Substances

Anti-Infective Agents
Hydroxychloroquine
Azithromycin